Genenta Science S.p.A. SAEN
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Genenta Science S.p.A. (SAEN) is a healthcare company listed in the US with a market value of about $31M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -33%.
About Genenta Science S.p.A.
Genenta Science S.p.A. is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 7 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Net income | -$8M | -$9M | -$13M | -$9M | -$6M | -$7M | -$5M |
| Free cash flow | -$8M | -$6M | -$12M | -$8M | -$8M | -$7M | — |
| EPS (diluted) | $-0.16 | $-0.19 | $-0.27 | $-0.19 | $-0.13 | $-0.14 | $-0.11 |
| Net margin | — | — | — | — | — | — | — |
| ROIC | -17.7% | -61.7% | -45.4% | -28.0% | -11.6% | -29.1% | -19.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Genenta Science S.p.A. pay a dividend?
Not currently.
Is Genenta Science S.p.A. a good stock to buy?
We do not give buy or sell advice. Genenta Science S.p.A. scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.